Introducing Noxopharm (ASX: NOX )

  • May 01, 2020 AEST
  • Team Kalkine

Introducing Noxopharm (ASX: NOX )

Noxopharm’s Breakthrough in Brain Cancer Program; Second Pipeline Drug Program Confirmed
In a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, paving the way to formally become the Company’s second pipeline drug program.

With proof-of-principle achieved, this Noxopharm program expects to confirm its lead candidate and proceed to a pre-clinical program with a target of entering a clinical study in late 2021.



The Video has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The current Video is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK